Update on Myelodysplastic Syndromes Classification and Prognosis

Surgical Pathology Clinics
Dita Gratzinger, Peter L Greenberg

Abstract

Myelodysplastic syndromes (MDS) are a collection of cytogenetically heterogeneous clonal bone marrow (BM) failure disorders derived from aberrant hematopoietic stem cells in the setting of an aberrant hematopoietic stem cell niche. Patients suffer from variably progressive and symptomatic bone marrow failure with a risk of leukemic transformation. Diagnosis of MDS has long been based on morphologic assessment and blast percentage as in the original French-American-British classification. The recently developed Revised International Prognostic Scoring System provides improved prognostication using more refined cytogenetic, marrow blast, and cytopenia parameters. With the advent of deep sequencing technologies, dozens of molecular abnormalities have been identified in MDS.

References

Jun 29, 1999·The Journal of Laboratory and Clinical Medicine·T B HaddyO Castro
Oct 9, 2002·Journal of Pediatric Hematology/oncology·Benjamin GesundheitMohamed Abdelhaleem
Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E VerburghG Verhoef
Jul 26, 2005·American Journal of Clinical Pathology·Monte S WillisSteven H Kroft
Sep 28, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca MalcovatiMario Cazzola
Dec 8, 2005·Pediatric Blood & Cancer·Sandrine Kagialis-GirardClaude Negrier
Aug 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca MalcovatiMario Cazzola
Jan 1, 2008·Blood Reviews·Inderjeet Dokal, Tom Vulliamy
Jan 23, 2008·American Journal of Clinical Pathology·Sepideh Maftoun-BanankhahWeina Chen
Apr 19, 2008·Internal Medicine·Yumiko OkaHideo Harigae
Dec 24, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matteo Giovanni Della PortaMario Cazzola
Jul 17, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T NösslingerM Pfeilstöcker
Mar 5, 2010·American Journal of Hematology·Barbara J Bain, David Nam
Sep 18, 2010·International Journal of Hematology·Hideo Harigae, Kazumichi Furuyama
Oct 26, 2010·Haematologica·Nicolaus KrögerUNKNOWN MDS Subcommittee of the Chronic Leukemia Working Party (CLWP) of the European Group for Blood and Marrow Transplantation (EB
May 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kiran NaqviMaria E Suarez-Almazor
Nov 15, 2011·Current Opinion in Hematology·John Lazarchick
Dec 14, 2011·Hematology·Charlotte M Niemeyer, Irith Baumann
Dec 20, 2011·Haematologica·Stefani ParmentierFrank Kroschinsky
Jan 6, 2012·International Journal of Hematology·Marc H G P Raaijmakers
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie SchanzDetlef Haase
Jun 29, 2012·The American Journal of Medicine·Xiaomei Ma

❮ Previous
Next ❯

Citations

Apr 19, 2016·International Journal of Molecular Sciences·Eugenia Flores-Figueroa, Dita Gratzinger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.